资料参考
LDK378是高度有效的间变性淋巴瘤激酶(ALK)(胰岛素受体超家族中的一种受体酪氨酸激酶)抑制剂,其IC50值为200 pM。LDK378也对其它激酶显示出中度到高度的抑制作用,其中,只有3种激酶的IC50值低于100 nM,包括IGF-1R(8 nM)、InsR(7 nM)和STK22D(23 nM)。据以往研究,在转染NPM-ALK融合基因的Ba/F3细胞以及携带NPM-ALK融合基因的Karpas-299人类非霍奇金Ki阳性大细胞淋巴瘤中,LDK378抑制细胞增殖,其IC50值分别为22.8 nM和26 nM。
参考文献:
[1]Chen J, Jiang C, Wang S. LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. J Med Chem. 2013 Jul 25;56(14):5673-4. doi: 10.1021/jm401005u. Epub 2013 Jul 9.
[2]Marsilje TH, Pei W, Chen B, Lu W, Uno T, Jin Y, Jiang T, Kim S, Li N, Warmuth M, Sarkisova Y, Sun F, Steffy A, Pferdekamper AC, Li AG, Joseph SB, Kim Y, Liu B, Tuntland T, Cui X, Gray NS, Steensma R, Wan Y, Jiang J, Chopiuk G, Li J, Gordon WP, Richmond W, Johnson K, Chang J, Groessl T, He YQ, Phimister A, Aycinena A, Lee CC, Bursulaya B, Karanewsky DS, Seidel HM, Harris JL, Michellys PY. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem. 2013 Jul 25;56(14):5675-90. doi: 10.1021/jm400402q. Epub 2013 Jun 26.